Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP increased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 298,700 shares of the biopharmaceutical company's stock after buying an additional 25,000 shares during the period. Two Sigma Advisers LP owned 0.39% of Xenon Pharmaceuticals worth $11,709,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. FMR LLC increased its stake in Xenon Pharmaceuticals by 8.8% during the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock worth $294,991,000 after acquiring an additional 607,606 shares during the last quarter. Boxer Capital Management LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth approximately $23,520,000. JPMorgan Chase & Co. increased its stake in Xenon Pharmaceuticals by 38.9% during the fourth quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company's stock worth $53,190,000 after acquiring an additional 380,112 shares during the last quarter. Stempoint Capital LP bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth approximately $14,733,000. Finally, Janus Henderson Group PLC increased its stake in Xenon Pharmaceuticals by 12.3% during the fourth quarter. Janus Henderson Group PLC now owns 2,866,755 shares of the biopharmaceutical company's stock worth $112,425,000 after acquiring an additional 314,363 shares during the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock traded down $0.31 during mid-day trading on Wednesday, reaching $29.15. 178,461 shares of the company were exchanged, compared to its average volume of 727,831. The business has a fifty day moving average of $33.41 and a 200 day moving average of $37.29. The firm has a market cap of $2.24 billion, a P/E ratio of -10.33 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million for the quarter, compared to analysts' expectations of $1.64 million. During the same quarter in the prior year, the company earned ($0.62) EPS. Sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on XENE. Needham & Company LLC cut their target price on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Wall Street Zen cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. HC Wainwright reiterated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Finally, Evercore ISI assumed coverage on Xenon Pharmaceuticals in a report on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price target for the company. One research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $54.82.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.